Involved-field radiation therapy for inoperable non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 25, Issue 35, 2007, Pages 5557-5561

  Rosenzweig, Kenneth E ^a   Sura, Sonal ^a   Jackson, Andrew ^a   Yorke, Ellen ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIATION DOSAGE; RADIOTHERAPY, CONFORMAL; TREATMENT OUTCOME;

EID: 37649016872     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.2191     Document Type: Article

References (30)

1. Choy H, Nabid A, Stea B, et al: Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer. J Clin Oncol 23:5918-5928, 2005
2. Emami B, Graham MV: Lung, in Perez C, Brady LW (eds): Principles and Practice of Radiation Oncology. New York, NY, Lippincott-Raven, 1998, pp 1181-1220
3. Marks LB, Prosnitz LR: Assessing the impact of elective regional radiotherapy on survival. Cancer J Sci Am 5:92-100, 1999
4. Pu AT, Harrison JM, Robertson JA, et al: The toxicity of elective nodal irradiation in the definitive treatment of non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 39:196, 1997 (abstr 2)
5. Rosenzweig KE, Fox JL, Leibel SA, et al: Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer 103:2118-2127, 2005
6. Rosenzweig KE, Mychalzhak B, Fuks Z, et al: Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using threedimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer. Cancer J 6:82-87, 2000
7. Rosenzweig KE, Sim SE, Mychalczak B, et al: Elective nodal irradiation in the treatment of non-small-call lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 50:681-685, 2001
8. Mohan R, Barest G, Breqster LJ, et al: A comprehensive three-dimensional radiation treatment planning system. Int J Radiat Oncol Biol Phys 15:481-495, 1988
9. Mohan R: Dose computations for three-dimensional radiation treatment planning. Australas Phys Eng Sci Med 12:241-251, 1989
10. Lyman JT: Complication probability as assessed from dose-volume histograms. Radiat Res Suppl S13-S19, 1985
11. Kutcher Gj, Burman C, Brewster L, et al: Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys 21:137-146, 1991
12. Burman C, Kutcher GJ, Emami B, et al: Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 21:123-135, 1991
13. Withers HR, Taylor JMG, Maciejewski B: Treatment volume and tissue tolerance. Int J Radiat Oncol Biol Phys 14:751-759, 1988
14. Yorke ED, Jackson A, Rosenzweig KE, et al: Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 54:329-339, 2002 (2 suppl)
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Zhao L, Chen M, Ten Haken R, et al: Three-dimensional conformal radiation may deliver considerable dose of incidental nodal irradiation in patients with early stage node-negative non-small cell lung cancer when the tumor is large and centrally located. Radiother Oncol 82:153-159, 2007
17. Perez CA, Pajak TF, Rubin P: Long-term observations of the patterns of failure with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Cancer 59:1874-1881, 1987
18. Emami B, Mirkovic N, Scott C, et al: The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: An analysis of RTOG data. Lung Cancer 41:207-214, 2003
19. Jeremic B, Shibamoto Y, Acimovic LJ, et al: Hyperfractionated radiotherapy alone for clinical stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 38:521-525, 1997
20. Jeremic B, Shibamoto Y, Acimovic LJ, et al: Hyperfractionated radiotherapy alone for clinical stage II non-small cell lung cancer. Radiother Oncol 51:141-145, 1999
21. Hayman JA, Martel MK, Ten Haken RK, et al: Dose escalation in non-small cell lung cancer using three-dimensional conformal radiation therapy: Update of a phase I trial. J Clin Oncol 19:127-136, 2001
22. Senan S, Burgers S, Samson MJ, et al: Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. Int J Radiat Oncol Biol Phys 54:999-1006, 2002
23. Sulman EP, Chang JY, Liao Z, et al: Exclusion of elective nodal irradiation does not decrease local regional control of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 63:S226-S227, 2005 (abstr 1)
24. Hayakawa K, Mitsuhashi N, Saito Y, et al: Limited field irradiation for medically inoperable patients with peripheral stage I non-small cell lung cancer. Lung Cancer 26:137-142, 1999
25. Cheung PCF, Mackillop WJ, Dixon P, et al: Involved-field radiotherapy alone for early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 48:703-710, 2000
26. Bradley JD, Wahab S, Lockett MA, et al: Elective nodal failures are uncommon in medically inoperable patients with stage I non-small-cell lung carcinoma treated with limited radiotherapy fields. Int J Radiat Oncol Biol Phys 56:342-347, 2003
27. Yuan S Sr, Yu J, Sun X Sr, et al: Three-dimensional conformal involved-field radiotherapy for stage III non-small cell lung cancer. J Clin Oncol 24:375s, 2006 (suppl; abstr 7044)
28. Martel MK, Sahijdak WM, Hayman JA, et al: Incidental dose to clinically negative nodes from conformal treatment fields for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 45:244, 1999 (abstr)
29. Jeremic B: Incidental irradiation of nodal regions at risk during limited-field radiotherapy (RT) in dose-escalation studies in non-small cell lung cancer (NSCLC): Enough to convert no-elective into elective nodal irradiation (ENI)? Radiother Oncol 71:123-125, 2004
30. Pu AT, Harrison AS, Robertson JM, et al: The toxicity of elective nodal irradiation in the definitive treatment of non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 39:196, 1997 (abstr)